1. Alkaloid

Sapropterin dihydrochloride (Synonyms: 6R-BH4 dihydrochloride; 6R-Tetrahydro-L-biopterin dihydrochloride)

Cat. No.: HY-A0124A Purity: >98.0%
Data Sheet SDS Handling Instructions

Sapropterin dihydrochloride is a synthetic form of BH4 that is approved for the treatment of BH4 responsive PKU.

For research use only. We do not sell to patients.
Sapropterin dihydrochloride Chemical Structure

Sapropterin dihydrochloride Chemical Structure

CAS No. : 69056-38-8

Size Price Stock Quantity
10 mM * 1 mL in Water $55 In-stock
10 mg $50 In-stock
50 mg $80 In-stock
100 mg $140 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Featured Recommendations

Related Screening Libraries:

  • Biological Activity

  • Technical Information

  • Purity & Documentation

  • References

Description

Sapropterin dihydrochloride is a synthetic form of BH4 that is approved for the treatment of BH4 responsive PKU. (1) Sapropterin dihydrochloride can stimulate TH and TPH activities leading to improved dopamine and serotonin synthesis despite persistently elevated brain phenylalanine. (2) Sapropterin dihydrochloride is used to lower blood phenylalanine levels in tetrahydrobiopterin-responsive phenylketonuria in conjunction with a phenylalanine-restricted diet.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00445978 BioMarin Pharmaceutical Sickle Cell Disease April 2007 Phase 2
NCT00423280 University of Oxford|BioMarin Pharmaceutical Coronary Artery Disease November 2006 Phase 2
NCT00532844 BioMarin Pharmaceutical Endothelial Dysfunction September 2007 Phase 2
NCT00802893 Johns Hopkins University|BioMarin Pharmaceutical Isolated Systolic Hypertension|Endothelial Dysfunction December 2008 Phase 2
NCT00403494 BioMarin Pharmaceutical Intermittent Claudication December 2006 Phase 2
NCT00325962 BioMarin Pharmaceutical Hypertension May 2006 Phase 2
NCT00435331 Vanderbilt University|National Institutes of Health (NIH)|BioMarin Pharmaceutical Pulmonary Arterial Hypertension March 2008 Phase 1
NCT02947750 Emory University|National Heart, Lung, and Blood Institute (NHLBI) Renal Insufficiency, Chronic October 2016 Phase 2
NCT00104247 BioMarin Pharmaceutical Phenylketonurias March 2005 Phase 3
NCT00445978 BioMarin Pharmaceutical Sickle Cell Disease April 2007 Phase 2
NCT00423280 University of Oxford|BioMarin Pharmaceutical Coronary Artery Disease November 2006 Phase 2
NCT00532844 BioMarin Pharmaceutical Endothelial Dysfunction September 2007 Phase 2
NCT00802893 Johns Hopkins University|BioMarin Pharmaceutical Isolated Systolic Hypertension|Endothelial Dysfunction December 2008 Phase 2
NCT00403494 BioMarin Pharmaceutical Intermittent Claudication December 2006 Phase 2
NCT00325962 BioMarin Pharmaceutical Hypertension May 2006 Phase 2
NCT00435331 Vanderbilt University|National Institutes of Health (NIH)|BioMarin Pharmaceutical Pulmonary Arterial Hypertension March 2008 Phase 1
NCT02947750 Emory University|National Heart, Lung, and Blood Institute (NHLBI) Renal Insufficiency, Chronic October 2016 Phase 2
NCT00104247 BioMarin Pharmaceutical Phenylketonurias March 2005 Phase 3
NCT00445978 BioMarin Pharmaceutical Sickle Cell Disease April 2007 Phase 2
NCT00423280 University of Oxford|BioMarin Pharmaceutical Coronary Artery Disease November 2006 Phase 2
NCT00532844 BioMarin Pharmaceutical Endothelial Dysfunction September 2007 Phase 2
NCT00802893 Johns Hopkins University|BioMarin Pharmaceutical Isolated Systolic Hypertension|Endothelial Dysfunction December 2008 Phase 2
NCT00403494 BioMarin Pharmaceutical Intermittent Claudication December 2006 Phase 2
NCT00325962 BioMarin Pharmaceutical Hypertension May 2006 Phase 2
NCT00435331 Vanderbilt University|National Institutes of Health (NIH)|BioMarin Pharmaceutical Pulmonary Arterial Hypertension March 2008 Phase 1
NCT02947750 Emory University|National Heart, Lung, and Blood Institute (NHLBI) Renal Insufficiency, Chronic October 2016 Phase 2
NCT00104247 BioMarin Pharmaceutical Phenylketonurias March 2005 Phase 3
NCT00730080 Washington University School of Medicine|BioMarin Pharmaceutical|University of Missouri-Columbia Phenylketonuria July 2008
NCT00964236 University of Missouri-Columbia|BioMarin Pharmaceutical Phenylketonuria August 2009
NCT01135186 Stanford University Gastroparesis May 2010
NCT00789568 BioMarin Pharmaceutical Phenylketonuria October 2008 Phase 1
NCT01977820 Merck KGaA Phenylketonuria February 2014 Phase 2
NCT00850070 The Children's Health Council|BioMarin Pharmaceutical Autistic Disorder March 2009 Phase 2
NCT01274026 Tulane University School of Medicine Phenylketonuria|Behavior and Behavior Mechanisms|PAH Gene Expression January 2011
NCT00484991 BioMarin Pharmaceutical Phenylketonuria
NCT01425528 University of Utah|BioMarin Pharmaceutical GTP Cyclohydrolase Deficiency August 2011 Phase 1|Phase 2
NCT00838435 BioMarin Pharmaceutical Phenylketonuria February 2009 Phase 3
NCT00986973 Children's Hospital of Philadelphia Phenylketonuria March 2010
NCT01541397 The University of Texas Health Science Center, Houston|BioMarin Pharmaceutical Hyperphenylalaninemia|Phenylketonuria June 2011
NCT01412437 Children's Research Institute|Georgetown University PKU April 2011
NCT00935753 University of California, San Diego|BioMarin Pharmaceutical Behavioral Manifestations of Lesch-Nyhan Disease Phase 2|Phase 3
NCT01114737 BioMarin Pharmaceutical Phenylketonuria August 2010 Phase 3
NCT01456286 Fundacion Clinic per a la Recerca Biomédica Liver Cirrhosis|Portal Hypertension October 2011 Phase 2|Phase 3
NCT00104260 BioMarin Pharmaceutical Phenylketonurias December 2004 Phase 2
NCT00272792 BioMarin Pharmaceutical Phenylketonurias February 2006 Phase 3
NCT00332189 BioMarin Pharmaceutical Phenylketonuria July 2006 Phase 3
NCT00225615 BioMarin Pharmaceutical Phenylketonurias November 2005 Phase 3
NCT01141595 The University of Texas Health Science Center, Houston|BioMarin Pharmaceutical Autism Spectrum Disorder July 2010
View MoreCollapse
References
Molecular Weight

314.17

Formula

C₉H₁₇Cl₂N₅O₃

CAS No.

69056-38-8

Storage
Powder -20°C 3 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O: ≥ 34 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sapropterin dihydrochloride
Cat. No.:
HY-A0124A
Quantity: